SAT0162 Switching from etanercept to CHS-0214: a one year, randomized, double-blind study in patients with rheumatoid arthritis
James R. O’Dell(University of Nebraska Medical Center), Barbara Finck(Coherus BioSciences (United States)), S. Nakashima(Daiichi-Sankyo (Japan)), Ingrid Louw(Cape Town Science Centre), Alan Kivitz(Altoona Center for Clinical Research), Tsutomu Takeuchi(Keio University), Т Д Тябут(9th City Clinical Hospital), Hong Tang(Coherus BioSciences (United States)), J Hodge(Coherus BioSciences (United States)), Yoshiya Tanaka(University of Occupational and Environmental Health Japan)
Cited by 3
Related Papers
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
|The Lancet|2000|1.5k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k